Can I read 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells on EtoBox?

820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells by Tacken, Paul ;Wang, Liang-chuan ;Klooster, Rinse ;Loo, Pieter Fokko Van ;Zhou, Jing ;Mondal, Arpita ;Liu, Yao-Bin ;Kramer, Arjen ;Condamine, Thomas ;Volgina, Alla ;Hendriks, Linda ;Maaden, Hans van der ;Rovers, Eric ;Engels, Steef ;Fransen, Floris ;Blanken-Smit, Renate den ;Zande, Vanessa Zondag-van der ;Basmeleh, Abdul ;Bartelink, Willem ;Kulkarni, Ashwini ;Marissen, Wilfred ;Huang, Cheng-Yen ;Hall, Leslie ;Harvey, Shane ;Kanellopoulou, Chrysi ;Stewart, Shaun ;Nastri, Horacio ;Bakker, Lex ;Logtenberg, Ton ;Plyte, Simon ;Mayes, Patrick ;Throsby, Mark ;Geuijen, Cecile is a Medicine article available to read on EtoBox.

What is 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells about?

Background MCLA-145 is a CD137 x PD-L1 bispecific antibody that releases PD-L1 mediated T-cell inhibition and activates and expands T cells through agonism of CD137. Immune checkpoint inhibitors (ICI) against PD-(L)1 have demonstrated anti-tumor efficacy in a fraction of patients across a broad range of cancers. CD137 (4-1BB, tumor necrosis factor receptor superfamily 9) is an inducible costimulatory receptor transiently expressed on T cells after TCR engagement. CD137 signaling is triggered by receptor clustering and leads to enhanced cytokine production; T cell proliferation, survival, and effector function; and immunological memory formation. Targeting of PD-L1 and CD137 with MCLA-145 may achieve synergistic activity by simultaneously blocking the inhibitory checkpoint PD-L1 and activating tumor specific T cells through co-stimulation. Methods We performed combinatorial functional screening of bispecific antibodies generated from high affinity inhibitory Fabs binding PD-L1 combined with a large and diverse panel of agonistic CD137 Fabs. Results MCLA-145 was selected based on its in vitro potency in multiple primary human immune cell assays. Further, it displays an ability to rev

Who reads 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells?

Author

Tacken, Paul ;Wang, Liang-chuan ;Klooster, Rinse ;Loo, Pieter Fokko Van ;Zhou, Jing ;Mondal, Arpita ;Liu, Yao-Bin ;Kramer, Arjen ;Condamine, Thomas ;Volgina, Alla ;Hendriks, Linda ;Maaden, Hans van der ;Rovers, Eric ;Engels, Steef ;Fransen, Floris ;Blanken-Smit, Renate den ;Zande, Vanessa Zondag-van der ;Basmeleh, Abdul ;Bartelink, Willem ;Kulkarni, Ashwini ;Marissen, Wilfred ;Huang, Cheng-Yen ;Hall, Leslie ;Harvey, Shane ;Kanellopoulou, Chrysi ;Stewart, Shaun ;Nastri, Horacio ;Bakker, Lex ;Logtenberg, Ton ;Plyte, Simon ;Mayes, Patrick ;Throsby, Mark ;Geuijen, Cecile

Publisher

BMJ Publishing Group Ltd

Published

2020

Language

EN

Field

Medicine (Health Sciences)